Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Sola Biosciences LLC has 3 pending office actions currently active in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct art units, indicating that the company's intellectual property strategy involves multiple sub-specialties within the broader biotech field. This distribution requires practitioners to navigate the specific procedural nuances of more than one unit simultaneously.
The portfolio's prosecution is handled by 3 distinct examiners, with each examiner managing exactly one of the pending actions. This lack of overlap between examiners means that the company must address 3 different sets of examiner preferences and historical patterns. There is no centralized examiner influence across the current pending docket, which may lead to varied prosecution timelines.
STOICA, ELLY GERALD is the busiest examiner for the portfolio, with 1 busiest examiner pending action. While this individual is the primary contact for a portion of the workload, they only account for 1 of the 3 total pending office actions. The remaining actions are handled by other examiners, maintaining a diverse spread of responsibility across the 3 distinct examiners involved.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STOICA, ELLY GERALD | 1 | 66.9% | +22.5% |
| JOHANSEN, PETER N. | 1 | 59.3% | +24.4% |
| LIEB, JEANETTE M | 1 | 79.9% | +17.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17997142 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF TDP-43 PROTEINOPATHIES | STOICA, ELLY GERALD | — |
| 17995901 | Compositions and Methods for the Treatment of Protein Aggregation Disorders | LIEB, JEANETTE M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18007978 | Compositions and Methods for the Treatment of Synucleinopathies | JOHANSEN, PETER N. | 85d overdue |
| 17997142 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF TDP-43 PROTEINOPATHIES | STOICA, ELLY GERALD | — |
| 17995901 | Compositions and Methods for the Treatment of Protein Aggregation Disorders | LIEB, JEANETTE M | — |
| Art Unit | Apps |
|---|---|
| 1654 | 2 |
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17997142 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF TDP-43 PROTEINOPATHIES | STOICA, ELLY GERALD | 1654 | §103§112 | Non-Final OA | — | Pending | May 12, 2023 |
| 18007978 | Compositions and Methods for the Treatment of Synucleinopathies | JOHANSEN, PETER N. | 1644 | §103DP | Final Rejection | 85d overdue | Pending | Dec 02, 2022 |
| 17995901 | Compositions and Methods for the Treatment of Protein Aggregation Disorders | LIEB, JEANETTE M | 1654 | §103§112 | Non-Final OA | — | Pending | Oct 10, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial